Suppr超能文献

家族性低钙血症性高钙血症

Familial Hypocalciuric Hypercalcemia

作者信息

Nava Suarez Corina C., Anastasopoulou Catherine, Kathuria Pranay

机构信息

The John's Hopkins Hospital

Jefferson Einstein Medical Center

Abstract

Familial hypocalciuric hypercalcemia (FHH) is a genetic condition characterized by mild hypercalcemia, typically found in otherwise healthy and asymptomatic individuals. Hypercalcemia is a common cause for referral and evaluation in medicine commonly encountered in routine serum chemistry. Differential diagnoses of hypercalcemia are usually based on the acuity and severity of presentation and concomitant level of serum parathyroid hormone (PTH). FHH arises from calcium-sensing receptor gene () mutations, leading to decreased receptor activity in response to serum calcium levels. This results in mild hypercalcemia, hypocalciuria, hypermagnesemia, and hypophosphatemia, with normal or slightly elevated serum PTH levels. FHH is usually benign and lacks the severe long-term consequences associated with other hypercalcemia syndromes. The condition's hallmark is an altered calcium-sensing mechanism, making the parathyroid glands less sensitive to calcium and requiring a higher serum calcium level to suppress PTH release. Increased calcium and magnesium reabsorption in the kidneys can also result.  Diagnosing FHH can be challenging due to its overlap with primary hyperparathyroidism (PHPT). Diagnostic evaluation usually includes family history, serum chemistry records, and 24-hour urine calcium excretion measurement. A calcium clearance to creatinine clearance ratio (Ca/Cr) of <0.01 is indicative of FHH in most cases. Genetic testing for mutations is recommended in ambiguous cases. While most FHH patients remain asymptomatic, those with symptoms may experience fatigue, weakness, constipation, polyuria, polydipsia, or headaches. FHH typically does not increase fracture risk, although there have been reports of intrauterine bone abnormalities, chondrocalcinosis, and pancreatitis in some patients. Treatment mainly involves patient education and reassurance, with calcimimetic medications like Cinacalcet-HCL or bisphosphonates used in more symptomatic cases despite not being FDA-approved for FHH.

摘要

家族性低钙尿性高钙血症(FHH)是一种遗传性疾病,其特征为轻度高钙血症,通常见于其他方面健康且无症状的个体。高钙血症是医学上常见的转诊和评估原因,在常规血清化学检查中经常遇到。高钙血症的鉴别诊断通常基于临床表现的急缓与严重程度以及血清甲状旁腺激素(PTH)的伴随水平。FHH源于钙敏感受体基因()突变,导致受体对血清钙水平的反应活性降低。这会导致轻度高钙血症、低钙尿症、高镁血症和低磷血症,血清PTH水平正常或略有升高。FHH通常为良性,缺乏与其他高钙血症综合征相关的严重长期后果。该疾病的标志是钙传感机制改变,使甲状旁腺对钙的敏感性降低,需要更高的血清钙水平来抑制PTH释放。肾脏中钙和镁重吸收增加也可能由此导致。由于FHH与原发性甲状旁腺功能亢进症(PHPT)存在重叠,诊断FHH可能具有挑战性。诊断评估通常包括家族史、血清化学记录以及24小时尿钙排泄量测量。在大多数情况下,钙清除率与肌酐清除率之比(Ca/Cr)<0.01表明为FHH。在不明确的病例中,建议进行基因检测以查找突变。虽然大多数FHH患者无症状,但有症状的患者可能会出现疲劳、虚弱、便秘、多尿、多饮或头痛。FHH通常不会增加骨折风险,尽管有报道称一些患者存在宫内骨骼异常、软骨钙质沉着症和胰腺炎。治疗主要包括对患者进行教育并给予安慰,在症状较明显的病例中可使用西那卡塞 - HCL等拟钙剂药物或双膦酸盐,尽管这些药物未获美国食品药品监督管理局(FDA)批准用于FHH。

相似文献

6
Case report: familial hypocalciuric hypercalcemia.病例报告:家族性低钙血症性高钙血症
AME Case Rep. 2024 Apr 10;8:55. doi: 10.21037/acr-23-132. eCollection 2024.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验